Cantor Fitzgerald Initiates Coverage On Rocket Pharmaceuticals with Overweight Rating, Announces Price Target of $65
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has initiated coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) with an Overweight rating and a price target of $65.
October 24, 2023 | 9:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rocket Pharmaceuticals has been given an Overweight rating and a price target of $65 by Cantor Fitzgerald.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for Rocket Pharmaceuticals. The price target of $65 suggests significant upside potential from the current price. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100